PROTEOME SCIENCES PLC (PRM) — Annual General Meeting

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen. Welcome to the Proteum Sciences PLC Annual General Meeting. Throughout this recorded meeting, attendees online will be in listen only mode. Questions are encouraged. They can be submitted at any time using the Q and A tab just situated on the right hand corner of your screen. Type in your questions and press send. I'd now like to hand over, if I may, to Christopher Pierce, Chairman. Good afternoon, sir. Thank you very much indeed. Ladies and gentlemen, now it's noon. Thank you for coming here to to attend our annual general meeting. I'm Christopher Pierce, as you heard, chairman, and I shall be chairing the meeting today. May I introduce those members of the board to you who are at this meeting? On my right, I've got Mariola Songin. To his right, we're very pleased to welcome for the first time, Abdul Amari, who joined us as finance director in September of last year. To the back to my right is Martin Diggle. Behind me, Richard Dennis, our chief commercial officer, Ian Pike, chief scientific officer, and Victoria First, our company secretary. Unfortunately, Roger McDowell, one of our directors, is unable to attend the meeting, and he sent his apologies to you all. Quorum for this annual general meeting is two members. As there are more than two members present, I declare the meeting open. I'll read you a short statement, which has been released on the RNS this morning. Questions relating to the AGM statement may be asked before moving to the formal business of the meeting. PROTEOME SCIENCE has had a strong performance in the year ended 12/31/2022, with total revenue increasing by 52% to 7,780,000. And in '21, it was 5,130,000. Biomarker services grew by 45% to 2,750,000, and TMT TMT PRO revenues increased 56% to 5 point naught 3,...